John F. Crowley Purchases 1,395 Shares of Amicus Therapeutics, Inc. (FOLD) Stock
Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley acquired 1,395 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, September 26th. The shares were bought at an average price of $14.36 per share, for a total transaction of $20,032.20. Following the transaction, the chief executive officer now owns 328,001 shares of the company’s stock, valued at approximately $4,710,094.36. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) traded up 2.59% during midday trading on Friday, hitting $15.08. The company had a trading volume of 3,277,493 shares. The stock’s market cap is $2.48 billion. The company’s 50 day moving average is $13.24 and its 200 day moving average is $9.90. Amicus Therapeutics, Inc. has a 12-month low of $4.41 and a 12-month high of $16.06.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. The firm had revenue of $7.16 million for the quarter, compared to analyst estimates of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same quarter in the previous year, the business posted ($0.40) earnings per share. On average, equities analysts anticipate that Amicus Therapeutics, Inc. will post ($1.31) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “John F. Crowley Purchases 1,395 Shares of Amicus Therapeutics, Inc. (FOLD) Stock” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/09/30/john-f-crowley-purchases-1395-shares-of-amicus-therapeutics-inc-fold-stock.html.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Teacher Retirement System of Texas grew its holdings in shares of Amicus Therapeutics by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 169 shares in the last quarter. DORCHESTER WEALTH MANAGEMENT Co acquired a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at $111,000. Tudor Investment Corp ET AL acquired a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at $124,000. Aperio Group LLC lifted its stake in shares of Amicus Therapeutics by 13.5% in the 2nd quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 1,663 shares during the last quarter. Finally, Zacks Investment Management acquired a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at $145,000.
A number of equities research analysts have commented on FOLD shares. Leerink Swann restated an “outperform” rating and issued a $17.00 target price (down previously from $18.00) on shares of Amicus Therapeutics in a research report on Saturday, September 16th. BidaskClub cut Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 2nd. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Cowen and Company reissued a “buy” rating and set a $16.00 target price (up from $10.00) on shares of Amicus Therapeutics in a research note on Tuesday, July 11th. Finally, Robert W. Baird reissued an “outperform” rating and set a $12.00 target price on shares of Amicus Therapeutics in a research note on Friday, June 30th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Amicus Therapeutics has an average rating of “Buy” and an average price target of $15.25.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.